New hope for older AML patients with FLT3 mutation: triple therapy trial underway
NCT ID NCT05520567
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 36 times
Summary
This study tests a combination of three drugs (gilteritinib, venetoclax, and azacitidine) in people newly diagnosed with a fast-growing type of acute myeloid leukemia (AML) who cannot have standard chemotherapy. The goal is to find the best dose and see how well the treatment controls the disease. About 70 participants will receive the drugs in cycles, and those who respond well may continue maintenance therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Nat'l Medical Center
Duarte, California, 91010, United States
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Cancer Institute
Pembroke Pines, Florida, 33028, United States
-
Motefiore-Einstein Center for Cancer Care
The Bronx, New York, 10461, United States
-
Novant Health
Winston-Salem, North Carolina, 27103, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois, 61612, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
Sarah Cannon Research Institute
Denver, Colorado, 80218, United States
-
The Medical College of Wisconsin- Froedtert Hospital
Milwaukee, Wisconsin, 53226, United States
-
The University of Texas MD
Houston, Texas, 77030, United States
-
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
-
UCLA Medical Center
Los Angeles, California, 90095, United States
-
Univ. of California - Irvine
Irvine, California, 92697, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Maryland
Baltimore, Maryland, 21201, United States
-
University of Pennsylvania-Abramson CCC-Dept. of Hem Onc
Philadelphia, Pennsylvania, 19104, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.